Ignite Creation Date:
2024-05-06 @ 9:35 AM
Last Modification Date:
2024-10-26 @ 12:16 PM
Study NCT ID:
NCT03011372
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-10
First Post:
2017-01-04
Brief Title:
A Study to Evaluate the Efficacy and Safety of Pemigatinib INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement - FIGHT-203
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Study Overview
Official Title:
A Phase 2 Open-Label Monotherapy Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib INCB054828 in Subjects With MyeloidLymphoid Neoplasms With FGFR1 Rearrangement - FIGHT-203
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03906357
Has Expanded Access, NCT# Status:
NO_LONGER_AVAILABLE
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of pemigatinib INCB054828 in subjects with myeloidlymphoid neoplasms with fibroblast growth factor receptor FGFR 1 rearrangement
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None